Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MenBvac
- Development stage
- Phase 4
- Lead developer
- Norwegian Institute of Public Health
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MenBvac is an outer membrane vesicle vaccine developed to prevent systemic meningococcal disease caused by serogroup B Neisseria meningitidis. Clinical studies have demonstrated that a four-dose regimen (three primary doses 6 weeks apart followed by a fourth booster dose a year later) provides good immunogenicity with prolonged persistence and increased cross-reactivity of functional antibodies. The vaccine has shown an acceptable safety profile with mild to moderate local and systemic reactions.
- Brand names
- MenBvac
- Other names
- MenBVac vaccineOuter membrane vesicle meningococcal B vaccineOMV-based meningococcal B vaccine
02
Targets
Neisseria meningitidis serogroup B outer membrane antigensNeuraminidase
Beyond the preview
Go deeper on MenBvac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MenBvac.